Please login to the form below
Royalty Pharma
This page shows the latest Royalty Pharma news and features for those working in and with pharma, biotech and healthcare.
Pfizer pays Royalty Pharma $475m following US approval of migraine nasal spray
Royalty Pharma signed a deal for the programme in 2020 with Biohaven, which Pfizer has since acquired. ... Pfizer has given Royalty Pharma an accelerated $475m milestone payment following the US approval of its migraine nasal spray, Zavzpret (zavegepant).
Latest news
-
Biogen and Genentech sign royalty agreement for blood cancer drug glofitamab
Genentech will have sole decision-making rights on glofitamab's commercialisation in the US
-
MorphoSys expands oncology pipeline with $1.7bn acquisition of Constellation Pharmaceuticals
MorphoSys has also entered into a long-term strategic funding partnership with Royalty Pharma. ... As part of this deal, Royalty Pharma will make a $1.425bn upfront payment to MorphoSys to support its growth strategy.
-
Forest Labs agrees $1.46bn deal to buy Furiex
Rights to these products will be sold on to Royalty Pharma AG for around $415m, helping to offset the Furiex purchase by around $315m, although Forest said the main Furiex deal
-
2013 - biotech boomed
The $10bn-plus strategic acquisition returned and pharma companies sought to replenish their pipelines. ... battle which had seen Elan resort to legal action to fend off hostile bids from US company Royalty Pharma.
-
Royalty Pharma buys bigger Tecfidera interest
Royalty Pharma has bought an interest in Biogen Idec's much-touted new oral multiple sclerosis (MS) therapy Tecfidera for $510m in cash. ... Royalty Pharma negotiated a similar earn-out agreement with former Fumapharm shareholders in May 2012, paying
More from news
Approximately 7 fully matching, plus 9 partially matching documents found.
Latest Intelligence
-
Deal Watch October 2018
Acquisition. $244m. Zealand/. Royalty Pharma. Royalty streams and milestones for Soliqua 100/33/. ... So two opportunities here – acquisition of animal health products and out-licensing to Bayer’s pharma business.
-
Deal Watch January 2018
Collaboration, licence. 310. Immunomedics/ Royalty Pharma. Royalty rights to sacituzumab govitecan (IMMU- 132) across all indications. ... In parallel Royalty Pharma also purchased $75m of Immunomedics shares at $17.15 per share (15% premium).
-
Deal Watch February 2017
The largest of these was Perrigo's divestment to Royalty Pharma of its royalty stream from Biogen's global sales of Tysabri (natalizumab), the multiple sclerosis antibody originally developed by Elan, ... Sale of Priority Review Voucher (PRV). 125.
-
Deal Watch March 2016
Only one other deal had an upfront value of more than $1bn: the sale by UCLA to Royalty Pharma of its royalty rights to Xtandi with a cash payment of ... Research collaboration. $2, 258. UCLA/ Royalty Pharma. Xtandi – androgen receptor inhibitor.
-
Deal Watch table for November 2014
For an indepth analysis of these deals, read'Pharma deals during November 2014'. ... Omega Pharma / Perrigo. OTC portfolio. Company acquisition. 4, 500. Cystic Fibrosis Foundation /Royalty Pharma.
More from intelligence
Approximately 0 fully matching, plus 14 partially matching documents found.
Subscribe to our email news alerts
- Market Access Director, six figure base salary and £5K joining b...
- Highly competitive salary
- Account Manager, 6 month contract, Healthcare Brand communicatio...
- Highly competitive salary
- Home Based Account Manager, Medical Communications, UK, Pharma/M...
- Highly competitive salary
- Account Director, Healthcare Marketing Creative Agency, Fixed te...
- Highly competitive salary
- Account Manager, Healthcare Marketing Creative Agency, Fixed ter...
- Highly competitive salary
- Senior Medical Copywriter - Highly Awarded Advertising Agency
- £50,000 - £60,000 yearly
- Novartis receives EC approval for Cosentyx in hidradenitis suppurativa
- Sanofi's frexalimab shows promise in relapsing forms of MS
- BMS and Janssen’s antithrombotic granted FDA fast track designation
- EMA recommends revoking marketing authorisation for Novartis’ sickle cell disease drug
- Amgen reports positive results for Otezla in psoriatic arthritis
- Supply chain challenges in 2023
- Whitepaper: Closing the gap with compelling healthcare communications
- Pfizer’s antibiotic combination shows promise in treating multi-drug resistant infections
- Supporting the most vulnerable: why pharma should get behind the NHS’ healthcare equity campaign
- Healing the Healers
- The (inevitable) digital transformation of Medical Affairs
- Novartis receives EC approval for Cosentyx in hidradenitis suppurativa
No results were found
PMHub
Evoke Mind+Matter
We are Evoke Mind ‘PLUS’ Matter. The ‘plus’ is important to us because we are all about offering more for...
Latest intelligence
- Whitepaper: Closing the gap with compelling healthcare communications
- Want to learn how to close the distance between a person’s current health and their healthiest possible self?...
- Healing the Healers
- Because if we do not heal the healers, who is going to heal us?...
- The (inevitable) digital transformation of Medical Affairs
- It’s not a question of ‘if,’ it’s a question of ‘when.’...
